T320-ADC / Nanolattix - LARVOL DELTA

Covariate-adjusted AP-1 motif architecture and footprinting track olaparib-adaptive chromatin remodelling. (PubMed, Front Syst Biol) - "At T320, 27,154 peaks gained and 30,050 lost accessibility. Exploratory nearest-TSS mapping of AP-1-rich gained peaks identified 899 protein-coding genes; recurring GO, Reactome and KEGG themes and STRING associations were used only to provide qualitative, hypothesis-generating functional context. Together, the data support a robust association between AP-1-compatible chromatin architecture and olaparib adaptation, while not establishing AP-1 occupancy, necessity or sufficiency in the studied cells."

Journal • Oncology • Ovarian Cancer • Solid Tumor

T320 tissue factor-targeted ADC from pre-clinical research to phase I clinical study. (ASCO 2026) - "Preclinical studies have demonstrated the potent anti-tumor efficacy and favorable pharmacokinetics and safety profile of T320. Early clinical data indicate manageable toxicity and promising activity, specifically highlighted by the durable stable disease observed in ovarian cancer. Further evaluation of T320 performance in the ongoing Phase I clinical study is expected."

ADC • P1 data • Preclinical • Constipation • Esophageal Cancer • Gastroenterology • Gastrointestinal Disorder • Oncology • Ovarian Cancer • Solid Tumor

An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients with Advanced Solid Tumor (ChiCTR) - P1 | N=144 | Recruiting | Sponsor: Cancer Hospital of Chinese Academy of Medical Sciences; Nanolattix Biotechnology Co., Ltd.

New P1 trial • Breast Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Nanolattix Biotechnology Co., Ltd.

First-in-human • New P1 trial • Breast Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Parent and Youth Perceptions of Family Environment Differentially Relate to Mental Health Outcomes (APA 2025) - "Youth reported higher conflict than parents (t[320]=3.44, p<.001); parents reported higher cohesion than youth (t[320]=-6.85, p<.001)... In this clinical sample, youth and parents significantly differed in their perceptions of family environment and associations between family environment and clinical outcomes differed by reporter. Future research is needed to assess how different perceptions of family environment relate to other mental health outcomes and how informant discrepancies influence provider assessment of psychiatric disorders and suicidality."

HEOR • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry